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Several homoplasmic pathologic mutations in mitochondrial DNA, such as those causing
Leber hereditary optic neuropathy or non-syndromic hearing loss, show incomplete
penetrance. Therefore, other elements must modify their pathogenicity. Discovery
of these modifying factors is not an easy task because in multifactorial diseases
conventional genetic approaches may not always be informative. Here, we have taken an
evolutionary approach to unmask putative modifying factors for a particular homoplasmic
pathologic mutation causing aminoglycoside-induced and non-syndromic hearing loss, the
m.1494C>T transition in the mitochondrial DNA. The mutation is located in the decoding
site of the mitochondrial ribosomal RNA. We first looked at mammalian species that
had fixed the human pathologic mutation. These mutations are called compensated
pathogenic deviations because an organism carrying one must also have another that
suppresses the deleterious effect of the first. We found that species from the primate
family Cercopithecidae (old world monkeys) harbor the m.1494T allele even if their
auditory function is normal. In humans the m.1494T allele increases the susceptibility
to aminoglycosides. However, in primary fibroblasts from a Cercopithecidae species,
aminoglycosides do not impair cell growth, respiratory complex IV activity and quantity or
the mitochondrial protein synthesis. Interestingly, this species also carries a fixed mutation
in the mitochondrial ribosomal protein S12. We show that the expression of this variant in
a human m.1494T cell line reduces its susceptibility to aminoglycosides. Because several
mutations in this human protein have been described, they may possibly explain the
absence of pathologic phenotype in some pedigree members with the most frequent
pathologic mutations in mitochondrial ribosomal RNA.
Keywords: mitochondrial ribosomal RNA, pathologic mutation, incomplete penetrance, aminoglycoside,
compensatory mutation, mitochondrial ribosomal protein S12, evolutionary approaches
INTRODUCTION
Human cells contain many mitochondria and each mitochon-
drion several mitochondrial DNA (mtDNA) molecules. The
absence of mtDNA genetic variation in a person is named homo-
plasmy. However, homoplasmic mutations can be found in a
particular individual when his/her mtDNA is different from a
reference sequence, the revised Cambridge Reference Sequence
(rCRS). If these mutations do not have phenotypic effect, they
can survive in the populations for long periods of time. On
the contrary, if mutations have very dramatic functional effects,
they will be very quickly removed from the populations. In
between, there are several pathologic mtDNA mutations with
moderate phenotypic effects. These are the etiologic factors for
some of the most frequent mtDNA diseases, such as the Leber
hereditary optic neuropathy (LHON) and the non-syndromic
hearing loss (NSHL) (Fischel-Ghodsian, 2000; Carelli et al.,
2003). A common feature for these homoplasmic mutations with
moderate functional effect is their tissue-specificity. For exam-
ple, despite being present in every mtDNA molecule of each
cell, LHON and NSHL mutations mainly affect retinal gan-
glion and cochlear cells, respectively. This fact suggests that
tissue-specific factors, including the specific set of expressed
proteins, are required for the manifestation of the pathologic
phenotype (Hamalainen et al., 2013). It is also frequently
found that maternal relatives of patients carrying homoplas-
mic mutations are asymptomatic. This fact, again, suggests that
other environmental and genetic factors are necessary for the
phenotypic expression (Fischel-Ghodsian, 2000; Carelli et al.,
2003).
The m.1494C>T mutation in the 12S rRNA gene (MT-RNR1)
was found in several NSHL patients from a Chinese family. The
oxygen consumption was lower in lymphoblastoid cell lines from
homoplasmic mutant individuals (Zhao et al., 2004). Moreover,
oxygen consumption and mtDNA-encoded protein synthesis was
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also lower in mutant transmitochondrial osteosarcoma 143B cell
lines (cybrids) (Zhao et al., 2005). Therefore, the biochemi-
cal phenotype was transferred with the mtDNA. As 12S rRNA
is required for the synthesis of mtDNA-encoded proteins and
all these polypeptides are part of the oxidative phosphorylation
(OXPHOS) system, the main oxygen consumer of the cell, these
results confirmed the pathogenicity of the m.1494C>T muta-
tion. Since then, homoplasmic m.1494C>T mutation has been
reported in 14 isolated NSHL patients and 22 Chinese and 3
Spanish NSHL pedigrees with different genetic background with
respect to mtDNA (Rodriguez-Ballesteros et al., 2006;Wang et al.,
2006; Chen et al., 2007, 2011; Han et al., 2007; Yuan et al., 2007;
Zhu et al., 2009; Wei et al., 2013a,b; Yang et al., 2013; Zhang
et al., 2013). A total of 533 maternal relatives of these 26 fami-
lies were studied, but 398 did not suffer from NSHL. Moreover,
this mutation was also found in a normal Chinese individual in a
population study to reconstruct the East AsianmtDNA phylogeny
(Kong et al., 2003).
The discovery of modifying factors that alter the penetrance of
mutations is not an easy task. Conventional genetic approaches
such as linkage analysis might not be informative when there
are many factors contributing to the disease (Carelli et al., 2003;
Hudson et al., 2007; Kirkman et al., 2009; Giordano et al.,
2011). We have recently found that m.1555G in the MT-RNR1
gene, which also provokes NSHL in humans (Prezant et al.,
1993), is the wild-type allele in orangutans and some other
mammalian species (Pacheu-Grau et al., 2011). These mutations
that have been fixed in other species are called compensated
pathogenic deviations (CPD) because, at this site, a nucleotide
or amino acid substitution would be pathogenic to humans and,
therefore, an organism carrying a CPD must also have some
other compensatory deviation with respect to humans that sup-
presses the deleterious effect of the CPD (Kondrashov et al.,
2002).
In order to find modifying factors affecting the penetrance
of the m.1494C>T transition, we looked for mammalian species
with the m.1494T allele and analyzed the mitochondrial transla-
tion system and OXPHOS function.
MATERIALS AND METHODS
BIOINFORMATICS STUDIES
We obtained 608 mammalian MT-RNR1 sequences pulled out
from completely sequenced mtDNAs published in GenBank
(http://www.ncbi.nlm.nih.gov/sites/entrez) until June 2014. We
also recovered 42 other total or partial Cercopithecidae
MT-RNR1 sequences from GenBank. 70 mammalian mito-
chondrial ribosomal protein S12 (MRPS12) sequences were
obtained from Ensembl (http://www.ensembl.org/index.html).
Sequence alignments were performed using themultiple sequence
alignment program ClustalW2 (http://www.ebi.ac.uk/Tools/msa/
clustalw2/). Conservation indexes were estimated as the percent-
age of sequences harboring the human wild-type variant. To
confirm the species origin of our cells, we also used Basic Local
Alignment Search Tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
The molecular model for ss-rRNA/RPS12 (PDB 2WDG) was
obtained with the Deep view/Swiss PDB viewer and the PyMOL
Molecular Graphics System, version 1.5.0.4 Schrödinger, LLC.
Human non-synonymous SNPs inMRPS12 were found in dbSNP
Home Page (http://www.ncbi.nlm.nih.gov/projects/SNP/).
CELL CULTURE CONDITIONS
Primary fibroblasts from macaque skin explant were expanded in
high-glucose (25mM) DMEM (Gibco-Life Technologies) supple-
mented with glutamine, pyruvate and fetal bovine serum 20%
(Gibco-Life Technologies) at 37◦C in a 5% CO2atmosphere.
For all cellular and biochemical studies, macaque cells were
grown 72 h in the same medium but lacking glucose and sup-
plemented with galactose 5mM. Human osteosarcoma 143B
cybrids were grown in high-glucose DMEMmedium (Gibco-Life
Technologies) supplemented with glutamine, pyruvate and fetal
bovine serum 5% (Gibco- Life Technologies). When required,
paromomycin (Sigma-Aldrich) 2 or 4mg/ml was added to the cell
culture.
KIRBY-BAUER DISK SUSCEPTIBILITY TEST
Analyses of bacterial susceptibility to paromomycin were per-
formed following the Kirby-Bauer procedure updated by the
Clinical Laboratory Standards Institute (Clinical Laboratory
Standards Institute, 2006). Cell cultures of the test organism
(Escherichia coli TG1) were grown to mid-log phase. Mueller-
Hinton agar plates were inoculated with 200µl of bacterial sus-
pension containing 3 × 108 CFU/ml. Mitochondrial preparations
from immortalized macaque cells were obtained as described
(Fernandez-Vizarra et al., 2010). Whatman paper discs (6mm
diameter) impregnated with 20µl of whole cell extracts or
mitochondria-enriched fractions (20µg protein/µl in PBS) were
placed on the agar surface. Inoculated plates were incubated for
14-16 h at 37◦C. Sensitivity to the antibiotic was demonstrated by
detecting a zone of growth inhibition.
HUMANMRPS12 CONSTRUCTS AND LENTIVIRAL TRANSDUCTION
cDNA was obtained by using the reverse transcription
system Transcriptor First Strand cDNA Synthesis Kit
(Roche), using total RNA extracted from cultured m.1555A
cybrids with TRIzol reagent (Invitrogen). MRPS12 cod-
ing sequence including the 5′ UTR sequence (Ensembl
Transcript ID: ENST00000407800) was PCR amplified
with Fw: GTTTAAACGCCACCATGTCCTGGTCTGGCC
and Rv: GTTTAAACTGTTTATTAAAACCCC primers.
The obtained PCR product was cloned into the pCR2.1
TOPO-TA cloning system (Invitrogen). A sequence checked
clone was used as template for site directed mutagene-
sis by using QuikChange® Site-Directed Mutagenesis Kit
(Stratagene) and the mutagenic primers: hMRPS12-R68L
Fw: CTGTGCACGTTTACCCTCAAGCCGAAGAAGCC and
hMRPS12-R68L Rv: GGCTTCTTCGGCTTGAGGGTAAACGTG
CACAG. Inserts with the correct sequences were subsequently
cloned into the lentiviral expression vector pWPI (Tronolab)
upstream of the ires-GFP coding sequence.
Lentiviral particles were generated in HEK 293T packaging
cells, and human cells were transduced with the formers as
described (Bayona-Bafaluy et al., 2011). Twenty-four hours after
transduction, GFP fluorescence was monitored by fluorescence
microscopy (Leica). GFP levels were also determined by Western
blot.
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MOLECULAR-GENETICS AND BIOCHEMICAL ANALYSIS
The sequencing of macaque 12S rRNA was done as previ-
ously described (Pacheu-Grau et al., 2011). To locate muta-
tions, the human rCRS (GenBank NC_012920) was used. The
sequencing of Cercopithecidae MRPS12 was also performed as
already explained (Pacheu-Grau et al., 2012), but using specific
primers for these species Fw: CACTAAGATCTGTTCTCTGCC
and Rv: ACTCCACAAGGGTTCACATC. To locate mutations,
the Macaca mulatta MRPS12 cDNA (Ensembl Transcript
Id: ENSMMUT00000038520) was used. Overexpressed vari-
ants of this gene were sequenced from cDNA with the
same primers used for cloning. The MRPS12 mRNA lev-
els were determined by quantitative PCR assays that were
carried out in a LightCycler 2.0 system (Roche), using
FastStart DNA MasterPLUS SYBR Green I (Roche) and primers
qMRPS12-36 Fw: AGGCAGCCACTCATGGATT, qMRPS12-36
Rv: GGCTTAATAGTGGTCCTGATGG.
For the determination of respiratory complex IV (CIV) activ-
ity and quantity (Mitoprofile® Human Complex IV Activity
and Quantity, Mitosciences, Invitrogen) CIV is immunocap-
tured within the wells and activity is determined colorimetrical
by the oxidation of reduced cytochrome c as an absorbance
decrease at 550 nm. Subsequently, in the same wells the quan-
tity of enzyme is measured by adding a CIV specific antibody
conjugated with alkaline phosphatase. The phosphatase changes
a substrate from colorless to yellow at 405 nm. Other molecu-
lar analyses, such as p.MT-CO1 levels, Western blots, or mito-
chondrial protein synthesis, were performed according protocols
previously described (Gomez-Duran et al., 2010; Pacheu-Grau
et al., 2011, 2013). For Western blots, primary antibodies were
against p.MT-CO1 (1:1000, 459600, Life Technologies), Actin
(1:2000, A2066, Sigma), TOM20 (1:200, sc-11415, Santa Cruz
Biotechnology), MRPS12 (1:2000, AV46301, Sigma) and p.MT-
CO1 and SDHA together (MitoBiogenesis™ In-Cell ELISA Kit
(IR), ABCAM ab110216).
The cell viability was measured using the Neutral Red kit
(Sigma-Aldrich) and conditions previously published (Repetto
et al., 2008). Briefly, cells were either treated with paromomycin 2
or 4mg/ml or left untreated for 72 h. Then, the cells were incu-
bated for 2 h with neutral red dye (3.3 g/l), washed with PBS
and treated with elution medium followed by gentle shaking for
10min. Aliquots of the resulting solutions were transferred to 96-
well plates, and the absorbance at 540 nm was recorded using a
NovoStar MBG Labtech microplate instrument.
STATISTICAL ANALYSES
The statistical package StatView 6.0 was used to perform all the
statistics. Data for mean, standard deviation and number of anal-
ysis or replicates are presented. The unpaired two-tailed t-test
was used to compare parameters. P-values lower than 0.05 were
considered statistically significant.
RESULTS
THE HUMAN PATHOLOGICAL ALLELE m.1494T IS FIXED IN
CERCOPITHECIDAE
To search for the presence of m.1494T inmammalians, we aligned
the MT-RNR1 gene of 608 mammalian species obtained from
complete mtDNA sequences of the NCBI RefSeq database. This
NSHL mutation was the wild-type allele in 64 of them and,
in particular, in 47 of 48 primates of the Cercopithecidae fam-
ily (Supplementary Material: Note 1). To corroborate that this
pathological mutation is the wild-type allele in primates from this
family, we extended our analysis to include 42 other MT-RNR1
sequences from different species of the Cercopithecidae family
obtained from non-complete mtDNA sequences. These 90 species
include members of the four tribes (Colobini -3- and Presbytini
-21-, Cercopithecini -32-, and Papionini -34-) from the two sub-
families (Colobinae and Cercopithecinae) of the Cercopithecidae
family (Perelman et al., 2011). All these species, except Papio
ursinus, contain thymine at m.1494 position (Supplementary
Material: Note 2). Therefore, we confirm that m.1494T is the
wild-type allele in this family. However, the auditory function in
these monkeys approaches that of humans, including middle ear,
cochlear and neural function (Fowler et al., 2010; Joris et al., 2011;
Dylla et al., 2013).
THE m.1494C NUCLEOTIDE IS IMPORTANT FOR THE 12S rRNA
FUNCTION
The m.1494C>T pathological mutation was probably fixed in
Cercopithecidae because it produces a post-reproductive pheno-
type and negative or purifying selection could not remove it from
the population. However, several deaf individuals of the previ-
ously described human pedigrees lost their hearing capacity in
reproductive years (Zhao et al., 2004; Rodriguez-Ballesteros et al.,
2006; Wang et al., 2006; Chen et al., 2007; Han et al., 2007; Yuan
et al., 2007; Zhu et al., 2009; Wei et al., 2013b).
MtDNA is inherited exclusively by maternal lineage and it
remains possible that deafness due to a pathological mutation is a
male-specific phenotype. In this scenario, negative selection act-
ing on males would not affect m.1494T population frequency in
the next generation (Frank and Hurst, 1996). However, 76 NSHL
individuals from these pedigrees were female (Zhao et al., 2004;
Rodriguez-Ballesteros et al., 2006; Wang et al., 2006; Chen et al.,
2007; Han et al., 2007; Yuan et al., 2007; Zhu et al., 2009;Wei et al.,
2013b).
These observations suggest that maternally inherited NSHL
phenotypemight be under selective pressure. In fact, them.1494C
position is conserved in 544 (89.5%) of 608 mammalian species
examined. This conservation index (CI) is higher than the
mean CI (77.6%) of the MT-RNR1 gene, considering the CI
of every position. Therefore, m.1494C nucleotide is functionally
important.
CERCOPITHECIDAE CELLS ARE RESISTANT TO AMINOGLYCOSIDES
It has been shown that aminoglycosides trigger NSHL in humans
harboring the m.1494C>T mutation. Thus, 50 out of 135
NSHL individuals from these pedigrees became deaf after a con-
firmed aminoglycosides exposure (Zhao et al., 2004; Rodriguez-
Ballesteros et al., 2006; Wang et al., 2006; Chen et al., 2007;
Han et al., 2007; Yuan et al., 2007; Zhu et al., 2009; Wei et al.,
2013b). In the bacterial rRNA the equivalent position to human
m.1494 forms a Watson-Crick base pair (W-C bp) with the
nucleotide in equivalent position to human m.1555, which are
both important for aminoglycoside binding. We have previously
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shown that aminoglycosides negatively affect OXPHOS func-
tion of orangutan cells, which harbor the m.1555G allele and
the W-C bp, by decreasing the synthesis of mtDNA-encoded
polypeptides and the CIV amount and activity. These drugs
also decrease the growth rate of orangutan cells (Pacheu-Grau
et al., 2011). Human wild-type 12S rRNA lacks this W-C bp,
but m.1494C>T mutation rebuilds it. Thus, mutant human 12S
rRNA is more similar to the bacterial rRNA and favors aminogly-
coside binding, which may produce toxic side-effects. Therefore,
the m.1494C>T mutation was likely fixed as the wild-type allele
in Cercopithecidae because they are not naturally exposed to
aminoglycosides.
To analyze the effect of aminoglycosides on OXPHOS function
of Cercopithecidae species, we first asked for primary fibroblasts
derived from skin explant from Macaca nemestrina (Papionini
tribe) and confirmed the origin of these cells and the exis-
tence of the mutation at m.1494 position. The sequencing of a
MT-RNR1 segment showed the presence of m.1494T nucleotide
(Figure 1A). In mammals, apart from Cercopithecidae family
and mutant humans, the m.1494T nucleotide has only been
described in 17 species from four different families (Notoryctidae,
Phascolarctidae, Elephantidae and Spalacidae) (Supplementary
FIGURE 2 | Paromomycin effect on macaque cells. Representative
images of macaque fibroblasts growing with different amount of
paromomycin (paro) and growth quantification. The number of cells after 3
days growing without aminoglycosides has been considered 100%.
FIGURE 1 | Electropherograms ofMT-RNR1 and MRPS12 partial sequences. (A) MT-RNR1 from Macaca sp. (B) MRPS12 from Macaca sp. and
Chlorocebus aethiops.
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FIGURE 3 | Paromomycin effect on OXPHOS complexes. (A) CIV specific
activity and quantity after treatment with paromomycin 2mg/ml. Dots line
represents values in the absence of the antibiotic. (B) p.MT-CO1 and actin
levels from macaque cells treated with paromomycin 0, 2, or 4mg/ml. (C)
Semiquantitative determination, by gel scanning, of p.MT-CO1/actin ratios
from macaque cells treated with paromomycin 0 (dot line), 2 or 4mg/ml. (D)
Representative image of p.MT-CO1 and SDHA levels from macaque cells
treated with paromomycin 0, 2 or 4mg/ml. (E) Quantitative determination, by
ELISA, of p.MT-CO1/SDHA ratios from macaque cells treated with
paromomycin 0, 2 or 4mg/ml. (F,G) Representative images of mitochondrial
translation products, and loading controls, from macaque cells treated with
paromomycin 0, 2, or 4mg/ml.
Material: Note 1). Another transition, m.1496T>C, is found in
all species from the Cercopithecinae subfamily and the Colobinae
Procolobus verus, but it is not found in any other mammalians
with m.1494C>T mutation. The Cercopithecidae origin of our
sample is supported by the m.1496T>C transition (Figure 1A).
Moreover, the match percentage between thisMT-RNR1 segment
(276 nucleotides, human 1302–1575 nucleotide positions) and
the one from Macaca nemestrina was 97%. However, this match
percentage reached 99% with that segment from Macaca silenus,
the phylogenetically closest species (Morales and Melnick, 1998;
Deinard and Smith, 2001; Perelman et al., 2011).
It has been reported that human immortalized lymphoblas-
toid cell lines and osteosarcoma 143B cybrids harboring the
m.1494C>Tmutation showed a decreased growth rate when cul-
tured with 2mg/ml of the aminoglycoside paromomycin (Zhao
et al., 2004, 2005). Human immortalized lymphoblastoid cell
lines and osteosarcoma 143B cybrids harboring the m.1555A>G
mutation, as well as orangutan primary fibroblasts from skin
explant containing m.1555G as the wild-type allele, also showed
FIGURE 4 | Mitochondrial fraction antibiogram. TOM20 is a
mitochondrial protein. CF, CF+P, MF, and MF+P code for cell fraction, cell
fraction from cells treated with paromomycin 2mg/ml, mitochondrial
fraction and mitochondrial fraction from cells treated with paromomycin
2mg/ml, respectively.
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a decreased growth rate and synthesis of mtDNA-encoded pro-
teins when cultured with 2mg/ml of paromomycin (Guan et al.,
2000; Giordano et al., 2002; Pacheu-Grau et al., 2011). However,
human osteosarcoma 143B cybrids and bonobo primary fibrob-
lasts from skin explant without any of these mutations were
resistant to 4mg/ml of paromomycin (Pacheu-Grau et al., 2011).
Therefore, we used 2 or 4mg/ml of paromomycin to analyze the
effect of aminoglycosides on macaque primary fibroblasts from
skin explant.
When oxidative metabolism is impaired, cells cultured in
galactose medium cannot synthesize the bulk of their ATP
requirements by glycolysis and the cell growth is inhibited
(Robinson et al., 1992). For this reason, we grew macaque
cells without or with paromomycin (2 or 4mg/ml) in galactose
medium, but we did not observe any differences in the growth
rate after 3 days (Figure 2).
To elucidate the effect of paromomycin on OXPHOS func-
tion, we determined CIV specific activity and levels, since catalytic
subunits of this complex are translated in mitochondrial ribo-
somes and are also required for CIV assembly. We did not observe
differences in these parameters when cells were grown with or
without the antibiotic (Figure 3A). The p.MT-CO1 polypeptide,
an mtDNA-encoded CIV subunit, was expressed at similar lev-
els in macaque cells grown without or with paromomycin (2 or
4mg/ml) (Figures 3B–E). Finally, the assays of mtDNA-encoded
protein synthesis did not differ between cells grown without
or with 2mg/ml paromomycin, although the levels of mtDNA-
encoded polypeptides were lower when cells were grown with
4mg/ml of paromomycin (Figures 3F,G).
To confirm that the antibiotic was incorporated into mito-
chondria, we performed an antibiogram of a mitochondria-
enriched fraction. The mitochondrial fraction showed a higher
inhibition of the bacterial growth than the cell homogenate
(Figure 4). This, along with the effect on mtDNA-encoded pro-
tein synthesis by high concentrations of paromomycin, supports
the presence of this antibiotic in the mitochondrial matrix.
These results indicate that paromomycin does not have impor-
tant effects on OXPHOS function of macaque cells and suggest
that Cercopithecidae cells are more resistant to paromomycin.
Therefore, m.1494C>T mutation should be compensated in this
species. Compensation would explain why auditory function in
macaques (Macaca nemestrina) and vervet monkeys (Chlorocebus
pygerythrus) was essentially unaffected by dihydrosptreptomycin
(Stebbins et al., 1987), although the patas monkey (Erythrocebus
patas), another member of Cercopithecidae, showed an impor-
tant susceptibility to the ototoxic action of dihydrostreptomycin
20mg/kg for 90 days (Hawkins et al., 1977). It is remarkable
that hearing damage is nearly universal when high drug lev-
els are present for prolonged periods (Fischel-Ghodsian, 2003).
The abundance of positively charged amino groups predestines
aminoglycosides to bind negatively charged molecules, such as
other non-ribosomal RNAs or phospholipids (Hermann, 2007;
Hainrichson et al., 2008). Therefore, the ototoxic effect in patas
monkey could be due to different mechanisms at high and pro-
longed aminoglycoside doses.
A MRPS12:R68L SUBSTITUTION COULD COMPENSATE THE
PATHOLOGICAL MUTATION m.1494C>T IN MACAQUE
Compensatory mutations have been proposed as probable expla-
nations for fixation of disease mutations in mtDNA-encoded
protein and tRNA genes (Kern and Kondrashov, 2004; Azevedo
et al., 2009). Compensatory mutations are also frequently found
in mtDNA-encoded rRNAs (Springer et al., 1995). As compen-
satory mutations usually appear in the same gene product as the
FIGURE 5 | Helix 39 of the 12S rRNA decoding site from Human
and Cercopithecidae. Blue number denotes helix numbering (Springer
and Douzery, 1996). The m.1494C>T transition, in the
yellow-encircled nucleotide position, is a human pathologic mutation
(m). Red nucleotides denote differences vs. the human sequence.
Green numbers indicate the absolute frequency of that nucleotide in
90 Cercopithecidae species. Several mutations have been
compensated in this helix 39.
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FIGURE 6 | MRPS12’s amino acid variation. (A) Protein alignment.
MRPS12 sequences from 4 Cercopithecidae species, Homo sapiens and
Thermus thermophilus. Red amino acids denote differences between human
and Cercopithecidae species. Yellow background indicates human
polymorphic positions. Underlined sequence is the mitochondrial targeting
sequence. (B,C) Molecular view of the interaction between the small subunit
rRNA (ss rRNA) and the ribosomal protein S12 in the Thermus thermophilus
ribosome. The mitochondrial 12S rRNA nucleotides (1494 and 1555, red and
green, respectively) and the MRPS12 amino acid variation between human
and macaque sequences (64, 68, 101, 106, 107, and 124) or the human
MRPS12 polymorphic amino acids (38, 44, 52, 55, 67, 68, 84, 115, and 125)
have been located in this bacterial structure.
CPD (Kondrashov et al., 2002), we analyzed the 12S rRNA decod-
ing site in Cercopithecidae. However, despite the existence of
compensatory mutations at helix 39 of the decoding site from the
Cercopithecidae rRNA, the m.1494C>T pathologic mutation has
not been compensated by an m.1555A>G transition (Figure 5).
Bacterial homolog of MRPS12, 30S ribosomal protein S12
(Rps12), is a critical component of the ribosomal decoding center
(Vila-Sanjurjo et al., 2007; Demirci et al., 2013). Compensatory
interactions between this ribosomal protein and bacterial rRNA
variants have already been reported (O’Connor et al., 1991). We
compared the human MRPS12 sequence with that from four
Cercopithecidae species and observed six variable amino acids
in the mature protein (Figure 6A). To confirm their functional
significance, we estimated their CIs using 70 mammalian species
(Supplementary Material: Note 3). The C64, R68, T101, Q106,
I107, and T124 CIs were 7.1, 90.0, 24.3, 10.0, 24.3, and 55.7%,
respectively. R68, with the highest CI, is present in 63 out of 70
mammalian species, includingChlorocebus sabaeus (Cercopithecus
sabeus), a member of the Cercopithecini tribe. However, 3 species
from the Papionini tribe contain L68 (Figure 6A). To confirm
the presence of L68 in the macaque MRPS12 protein and its
absence in members of the Cercopithecini tribe, we sequenced
this gene in the macaque primary fibroblasts and the Chlorocebus
aethiops COS-1 cell line (GenBank: KM885248 and KM885249)
(Figure 1B). Between our macaque sequence and the one from
Macaca mulatta or Macaca fascicularis we found one amino acid
difference (V107I). We found no amino acid differences between
the Chlorocebus aethiops sequence and the one from Chlorocebus
sabaeus (Figure 6A). Thus, the MRPS12:L68 was found in four
species of the Papionini tribe but it was not present in two of the
Cercopithecini tribe.
To check potential interactions between these MRPS12 amino
acids and the 12S rRNA m.1494 nucleotide, we located them in
the crystal structure of a bacterial (Thermus thermophilus) ribo-
some (Figure 6A). The position equivalent to amino acid 68 is
located less than 6 Å from m.1494 nucleotide whereas the other
polymorphic positions are far away from m.1494 (Figure 6B).
Moreover, some mutations in Escherichia coli Rps12, equiva-
lent to positions 64, 68, 106, and 124 in mammals, provide
a restrictive phenotype that confers resistance to the error-
inducing aminoglycosides (Maisnier-Patin et al., 2007; Agarwal
et al., 2011). Therefore, these potential aminoglycoside-resistance
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mutations in macaque MRPS12 could possibly compensate the
aminoglycoside-susceptibility mutation in 12S rRNA.
GENETIC MRPS12 VARIATION AS A MODIFIER FACTOR TO EXPLAIN
THE INCOMPLETE PENETRANCE OF m.1494C>T OR m.1555A>G
TRANSITIONS IN HUMANS
The results above suggested that variation in MRPS12 could
be a phenotype-modifying factor for mtDNA-inherited NSHL
mutations. In humans, 15 non-synonymous MRPS12 variants
have been described (4 of them in the mitochondrial target-
ing sequence: rs143032757, G5S; rs33988199, H8R; rs199548036n
T15I and rs150096976, R23W and 11 in the mature protein:
rs375680427 and rs201447868, R38C and R38H; rs147007310 and
rs375471558, R44G and R44Q; rs368555992, T52M, rs374146379,
R55Q; rs111688400, T67S; rs147184696, R68C; rs140018981,
R84W; rs202014859, T115A; and rs143918075, V125I). To assess
their functional importance, we estimated the CIs for R38,
R44, T52, R55, T67, R68, R84, T115, and V125 in 70 mam-
malian species (Supplementary Material: Note 3). Their CIs
were 92.9, 41.4, 92.9, 95.7, 28.6, 90.0, 94.3, 97.1, and 87.1%,
respectively. The mean CI of these variant positions (80%) is
significantly higher than that of the Cercopithecidae variants
(35.2%). Then, to check potential interactions between these
MRPS12 amino acids and the 12S rRNA m.1494 nucleotide, we
located them in the crystal structure of a bacterial (Thermus
thermophilus) ribosome (Figure 6C). As previously mentioned,
the bacterial protein position equivalent to 68-amino acid is
located less than 6 Å from m.1494 nucleotide but the other
human polymorphic positions reside far away from m.1494.
Mutations in the Escherichia coli Rps12 equivalent to positions 52
and 68 in mammals confer resistance to error-inducing amino-
glycosides (Agarwal et al., 2011). Therefore, several MRPS12
positions are possible modifiers for MT-RNR1 mutations in
humans.
THE MRPS12:R68L SUBSTITUTION MODIFIES THE PHENOTYPE OF THE
PATHOLOGICAL MUTATION m.1555A>G IN CULTURED CELLS
Ideally, to confirm a modifying role for an amino acid substitu-
tion in the MRPS12 in mt-rRNA inherited NSHL, homoplasmic
mutant maternal relatives suffering or not aminoglycosides trig-
gered deafness should be genotyped. However, in none of the
published pedigrees it was reported whether hearing individuals
were treated with aminoglycosides (Zhao et al., 2004; Rodriguez-
Ballesteros et al., 2006; Wang et al., 2006; Chen et al., 2007; Han
et al., 2007; Yuan et al., 2007; Zhu et al., 2009; Wei et al., 2013b).
In a previous work, we sequenced the MRPS12 protein in 21
Ménière disease patients who suffered a chemical labyrinthec-
tomy by using gentamycin. Ten became deaf and eleven retained
their hearing ability. However, they did not have the mt-rRNA
pathogenic mutation and we did not discover amino acid sub-
stitutions that could explain the phenotype (Pacheu-Grau et al.,
2012).
To confirm the potential modifying role of this MRPS12:R68L
variant, human cybrid cell lines harboring either the m.1555A or
the m.1555G alleles were transfected with the human wild-type
MRPS12 cDNA or its mutated version harboring the macaque
L68 substitution. The MRPS12 mRNA levels were at least 10
FIGURE 7 | MRPS12 expression. (A) MRPS12 mRNA levels. The levels of
non-transfected cells are considered 100%. (B) MRPS12 codon 68. Leu and
Arg code for leucine and arginine, respectively. (C) Relative amount of
MRPS12 and Actin proteins.
times higher than those of the non-transfected cells (Figure 7A).
Sequence analysis of RT-PCR products derived of these mRNAs
showed the presence of only one type of mRNA. Sanger sequenc-
ing is not sensitive enough to detect the low amounts of cDNA
raising from the endogenous allele, which is masked by the
huge amount of cDNA raising from the transfected transgene
(Figure 7B). The levels of the MRPS12 polypeptide were simi-
lar in all the transfected cell lines (Figure 7C). These cell lines
were grown in the presence or absence of paromomycin and
mitochondrial synthesis of proteins was evaluated. However, the
assay is semiquantitative and did not provide a clear result
(Figure 8A). Then, we determined CIV activity normalized by
citrate synthase (CS) activity. This ratio was significantly higher
(P = 0.027) in non-transfected wild-type than mutant cells but
the aminoglycoside did not have a significant effect on any of
these activities (Figure 8B), confirming a similar result by oth-
ers (Giordano et al., 2002). On the other hand, the ratio was
significantly higher in paromomycin-treated cells that harbor the
m.1555A 12S rRNA allele and overexpress the R68 MRPS12 vari-
ant (12S rRNA m.1555A-MRPS12R68R) than in the same cells
without paromomycin (Figure 8C). However, this activity was
significantly lower in paromomycin-treated cells that harbor the
m.1555G 12S rRNA allele and overexpress the R68 MRPS12
variant (12S rRNA m.1555G-MRPS12R68R) than in the same
untreated cells (Figure 8C). Taken together, the results above
showed that the R68 or L68 MRPS12 overexpression in wild-
type (m.1555A 12S rRNA) or mutant (m.1555G 12S rRNA) cells,
respectively, increases the resistance against paromomycin. There
is, apparently, a combination of 12S rRNA and MRPS12 posi-
tions that protect against aminoglycosides. Thus, the W-C bp
1494–1555 along with L68 MRPS12 or the lack of W-C bp in
these positions along with R68 MRPS12 increases the resistance
to paromomycin.
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FIGURE 8 | Paromomycin effect on OXPHOS proteins of MRPS12
transfected cells. (A) Mitochondrial translation products (right panel)
and loading controls (left panel). AR, AL, GR, GL, ARp, ALp, GRp, and
GLp code for 12S rRNA m.1555A-MRPS12R68R, 12S rRNA
m.1555A-MRPS12R68L, 12S rRNA m.1555G-MRPS12R68R, 12S rRNA
m.1555G-MRPS12R68L cells grown without or with paromomycin (p),
respectively. (B) CIV/CS ratio of wild-type (m.1555A 12S rRNA) and
mutant (m.1555G 12S rRNA) osteosarcoma 143B cybrids exposed or
not to paromomycin. (C) CIV/CS ratio of wild-type (m.1555A 12S rRNA)
and mutant (m.1555G 12S rRNA) osteosarcoma 143B cybrids that
overexpress the R68 or L68 MRPS12 variants exposed or not to
paromomycin. Asterisks denote P ≤ 0.0414.
DISCUSSION
We have shown that an amino acid substitution in the MRPS12
position 68 can compensate functional effects of 12S rRNA patho-
logic mutations m.1494C>T and m.1555A>G.
Several scenarios have been proposed to explain the co-
occurrence of CPDs and compensatory mutations. In the first
one, it has been suggested that a compensatory mutation could
be phenotypically neutral and stable, thus fixing itself quickly
in the population. On the other hand, a pathogenic mutation
would be unstable and become fixed only if it would occur after
the compensation mutation (Depristo et al., 2005). However,
the possible MRPS12:R68L compensatory mutation appears to
be an aminoglycoside-resistance mutation. Aminoglycosides pro-
duce misreading of the genetic code. In bacteria, this mutation
would increase the accuracy of translation but the improved
fidelity in such mutants is offset by their typically slower growth
and decreased rates of protein synthesis (Agarwal et al., 2011).
Resistance to antibiotics is usually associated with a fitness cost
(Maisnier-Patin and Andersson, 2004). Therefore, this mutation
may not be phenotypically neutral, would be target of negative
selection and be removed before the appearance of the m.1494
mutation. In the second scenario, both CPD and compensatory
mutations are individually deleterious, but together have a neutral
effect (Depristo et al., 2005). Therefore, they should be simulta-
neously present in the population. Most of mtDNA pathologic
mutations are recessive and require a certain percentage of het-
eroplasmy (mix of wild-type and mutant mtDNA genomes) to
produce a phenotype. Moreover, nuclear DNA (nDNA) muta-
tions can be found in heterozygosity. These two conditions,
heteroplasmy and heterozygosity, may allow the fixation of both
mutations at the same time. However, the presence of m.1494T in
all Cercopithecidae but the absence of MRPS12:L68 in monkeys
from the Cercopithecini tribe suggests that the mitochondrial
pathologic transition was older than the nuclear compensation
(Figure 9). Because Hominoidea diverged from Cercopithecoidea
32 million years ago and divergence time for Cercopithecoidea
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FIGURE 9 | Primates’ phylogeny. Numbers indicate million of years. This tree is based in Figure 2 from Perelman et al. (2011).
species is 18 million years (Perelman et al., 2011), the range of age
for the appearance of this m.1494C>T mutation is 32–18 million
years ago. However, the MRPS12:R68L compensatory mutation
had to be fixed between 12 (it is not present in Cercopithecini)
and 8 million years ago (it is found in Papionini tribe that
diverged 8 million years ago) (Perelman et al., 2011). Thus, at
least 6 million years passed between the fixation of these mt-
rRNA andMRPS12mutations. Up to now, there are not any other
published Cercopithecini MRPS12 sequences out of those for two
Chlorocebus (Cercopithecus) species, and we could not genotype
anymember of the Colobinae subfamily. If Colobinae species har-
bor a MRPS12 L68 amino acid, it would be possible that both 12S
rRNAm.1494C>T andMRPS12 R68L mutations appeared at the
same time, but the MRPS12 position reverted in the Chlorocebus
species.
Considering that the previous scenario may be wrong, how
can we explain that the compensatory mutation occurred after
the fixation of the deleterious mutation? A potential explana-
tion, functional epistasis, has been suggested for a homoplasmic
pathologic mutation that affects another important component
of mitochondrial translation system, the tRNAIle. This mutation
can induce a compensatory response by increasing mitochon-
drial biogenesis. Those individuals that are not able to have this
compensatory response developed a mitochondrial disease but
some women harboring this mutation would be able to increase
mitochondrial biogenesis, survive, reproduce, and transmit the
mutation to their descendants. The same options would be open
for individuals of the next generation. In this way, the probability
to fix another mutation that structurally compensated the patho-
logic one would increase (Moreno-Loshuertos et al., 2011).
Independently of the mechanism to fix a compensatory muta-
tion of a CPD, an analysis of MRPs’ evolution suggests that
genetic compensation is probably very common. Despite mtDNA
is evolving much faster than nDNA, MRPs are evolving at a rate
comparable to that of mt-rRNAs. MRPs also evolve at a higher
rate than cytosolic ribosomal proteins although both cytosolic
and mitochondrial sets of ribosomal proteins are encoded by
nDNA genes. Comparison of the ribosomal protein and rRNA
rates of evolution suggests that the changes are being fixed at
comparable rates, despite the different mutational rates for the
RNA and protein and for the two genomes (Matthews et al., 1978;
Pietromonaco et al., 1986). Similar to the high evolution rates
of nDNA-encoded MRPs to accommodate the mtDNA-encoded
rRNAs evolution rates (Pietromonaco et al., 1986), nDNA-
encoded mitochondrial aminoacyl-tRNA synthetases have also
higher evolution rates than nDNA-encoded cytosolic aminoacyl-
tRNA synthetases to accommodate the mtDNA-encoded tRNAs
evolution rates (Brindefalk et al., 2007; Frenkel-Morgenstern
et al., 2009). Moreover, nDNA-encoded OXPHOS complex sub-
units evolve faster than other nDNA-encoded proteins to accom-
modate the evolution of mtDNA-encoded OXPHOS complex
subunits (Osada and Akashi, 2012). Therefore, genetic variants of
nDNA frequently compensate pathologic mtDNA mutations. In
this sense, m.1494C>T and m.1555A>G are pathologic human
mutations with incomplete penetrance and one potential modi-
fying factor of this mutation, MRPS12 residue 68, has been found
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polymorphic in humans. Interestingly, we have found that CIs
of human MRPS12 variant positions are higher than those of
variant positions between human and Cercopithecidae. This sug-
gests that these human variants alter function and are negatively
selected, and only variants with lower CI (i.e., with lower phe-
notypic effect) survive. Therefore, amino acid substitutions in
MRPS12 or other mitochondrial ribosomal proteins are interest-
ing candidates to explain the incomplete penetrance of pathologic
mt-rRNA mutations.
The expansion of sequence and molecular structure databases
will undoubtedly facilitate the use of non-genetically manipulated
animal models harboring CPD to unmask modifying factors for
many homoplasmic mtDNA mutants.
AUTHOR NOTE
During the review of this manuscript, one of the referees made us
note that an MRPS12 sequence from the Colobinae Rhinopithecus
roxellana had been recently released in GenBank. The presence of
an arginine at MRPS12 position 68 from this Colobinae species
strongly supports that leucine 68 was fixed in the Papionini tribe
after its divergence from the Cercopithecini tribe.
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